The interim leader of an embattled Australian healthcare giant has assured shareholders the company will return to growth, despite posting a dizzying $3.7 billion annual loss.
Blood plasma product manufacturer CSL's share price has tumbled by about 70 per cent in the two years since July 2024, as it faced softening demand from key markets in the US and China, a major restructure and a wave of downgrades.
